Immutep Limited (IMMP)

AU — Healthcare Sector

Peers: PRQR CADL ALLO CAPR EDIT MREO VNDA CABA ACHV TRDA

Automate Your Wheel Strategy on IMMP

With Tiblio's Option Bot, you can configure your own wheel strategy including IMMP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol IMMP
Rev/Share 0.0346
Book/Share 0.9848
PB 4.4295
Debt/Equity 0.0113
CurrentRatio 11.6858
ROIC -0.8687

MktCap 642063124.4438
FreeCF/Share -0.4257
PFCF -10.3399
PE -10.3562
Debt/Assets 0.0104
DivYield 0
ROE -0.3887

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 1
P/B Score 3
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

IMMP
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

SYDNEY, AUSTRALIA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.

image for news Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Immutep Limited: Surging On Positive Head And Neck Data

IMMP
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive

Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncertain, with future trials and FDA discussions critical for potential accelerated approval.

image for news Immutep Limited: Surging On Positive Head And Neck Data

About Immutep Limited (IMMP)

IPO Date 2012-04-19
Website https://www.immutep.com
Industry Biotechnology
CEO Marc Voigt
Employees 41

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.